预约演示
FDA grants orphan drug status for Ichnos’ multiple myeloma antibody
2023-07-10
孤儿药临床1期免疫疗法细胞疗法
ISB 2001 is intended for patients with multiple myeloma. Credit: David A Litman via Shutterstock.com.
The US Food and Drug Administration (FDmultiple myelomarphan drug designation (ODD) for Ichnos Sciences’ ISB 2001 to treat patients with multiple myeloma.
ISB 200Food and Drug Administration (FDA)c antibody.multiple myeloma
Recommended Reports
ReportsLOA and PTSR Model - Anetumab Corixetan in Malignant Mesothelioma GlobalData
ReportsLOA and PTSR Model - Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma GlobalData
View allCompanies IntelligenAnetumab CorixetanIncVMalignant Mesothelioma
The company will commence a first-in-human Phase I dose-escalation, dose-expansion clinical trial of the antibody in 2023, once clearance has been given by the Australian Human Research Ethics Committee and the FDA’s approval has been received for its investigational new drug application.
ISB 2001 is the third clinicMipasetamab UzoptirinecompMalignant Fibrous Histiocytomaultiple myeloma.
In March 2023, the company’s ISB 1442, a CD38 x CD47 biparatopic bispecific antibody innate cell modulator, also received ODD from the FDA.
Ichnos Sciences president and CEO Cyril Konto stated: “The FDA’s decision to grant orphan drug designation to ISB 2001 – our third clinical-stage asset to receive that designation in five years – underscores theFDAportance of the work our team is doing to develop potentially curative therapies for the treatment of multiple myeloma.
“As new multiple myeloma diagnoses continue to climb, our charge of providing patiemultiple myelomaive, novel therapies that can overcome the limitations of options available to them today becomes that much more urgent.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。